2. GPCR/G Protein Neuronal Signaling Immunology/Inflammation
  3. Histamine Receptor
  4. IGN-2098

IGN-2098 is an orally active, competitive histamine H2 receptor antagonist with a pA2 value of 7.32. IGN-2098 inhibits basal and stimulated gastric acid secretion. IGN-2098 accelerates ulcer healing, suppresses ulcer edge elevation, and protects gastric and duodenal mucosa from damage. IGN-2098 can be used in research related to gastric ulcers.

For research use only. We do not sell to patients.

IGN-2098

IGN-2098 Chemical Structure

CAS No. : 126869-04-3

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

IGN-2098 Related Antibodies

Top Publications Citing Use of Products

View All Histamine Receptor Isoform Specific Products:

View All Isoforms
H1 Receptor H2 Receptor H3 Receptor H4 Receptor Histamine Receptor

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

IGN-2098 is an orally active, competitive histamine H2 receptor antagonist with a pA2 value of 7.32. IGN-2098 inhibits basal and stimulated gastric acid secretion. IGN-2098 accelerates ulcer healing, suppresses ulcer edge elevation, and protects gastric and duodenal mucosa from damage. IGN-2098 can be used in research related to gastric ulcers[1][2].

IC50 & Target[1]

H2 Receptor

7.32 (pA2)

In Vitro

IGN-2098 competitively antagonizes histamine H2 receptors in isolated guinea pig atrial specimens with a pA2 value of 7.32[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

IGN-2098 Related Antibodies
In Vivo

IGN-2098 (10-30 mg/kg; p.o.; twice daily; 14 days) dose-dependently accelerates the healing of acetic acid-induced gastric ulcers in rats, with 10 mg/kg and 30 mg/kg doses achieving 49.6% and 52.7% healing ratios respectively, and significantly reduces ulcer edge prominence compared to controls[1].
IGN-2098 (1-60 mg/kg; p.o., s.c., i.d., i.p.; single dose) potently inhibits basal gastric secretion in pylorus-ligated rats across multiple routes, with subcutaneous administration showing the highest potency (ED50 0.7 mg/kg for acid output inhibition)[2].
IGN-2098 (0.1-30 mg/kg; s.c.; single dose) potently inhibits histamine-stimulated gastric acid secretion in acute fistula rats, with an ED50 of 0.2 mg/kg[2].
IGN-2098 (0.3-30 mg/kg; s.c.; single dose) potently inhibits Carbachol (HY-B1208)-stimulated gastric acid secretion in acute fistula rats, with an ED50 of 0.3 mg/kg[2].
IGN-2098 (1-30 mg/kg; s.c.; single dose) potently inhibits Pentagastrin (HY-A0261)-stimulated gastric acid secretion in acute fistula rats, with an ED50 of 0.1 mg/kg[2].
IGN-2098 (3-60 mg/kg; s.c.; single dose) inhibits 2-deoxy-D-glucose (HY-13966)-stimulated gastric acid secretion in anesthetized rats, with an ED50 of 42.7 mg/kg[2].
IGN-2098 (3-60 mg/kg; p.o., s.c.; single dose) inhibits pylorus ligation-induced gastric ulcers in rats, with an ED50 of 29.7 mg/kg[2].
IGN-2098 (1-60 mg/kg; p.o.; single dose) inhibits water-immersion stress-induced gastric mucosal injury in rats, with an ED50 of 8.4 mg/kg[2].
IGN-2098 (0.3-3 mg/kg; p.o.; single dose) potently inhibits histamine-induced gastric mucosal injury in rats, with an ED50 of 0.9 mg/kg[2].
IGN-2098 (3-30 mg/kg; p.o.; single dose) inhibits Indomethacin (HY-14397)-induced gastric mucosal injury in rats, with an ED50 of 5.4 mg/kg[2].
IGN-2098 (1-30 mg/kg; p.o.; single dose) potently inhibits HCl-Aspirin (HY-14654)-induced gastric mucosal injury in rats, with an ED50 of 1.4 mg/kg, making it 8.1 times more potent than roxatidine[2].
IGN-2098 (3-60 mg/kg; p.o.; single dose) inhibits HCl-ethanol-induced gastric mucosal injury in rats, with an ED50 of 17.0 mg/kg[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Sprague-Dawley (male, 7 weeks old, gastric ulcer induced by 20% acetic acid injection)[1]
Dosage: 10 mg/kg; 30 mg/kg
Administration: p.o.; twice daily; 14 days
Result: Reduced mean ulcer index to 6.4 mm2 and achieved a 49.6% healing ratio at 10 mg/kg, with a significant difference versus control.
Reduced mean ulcer index to 6.0 mm2 and achieved a 52.7% healing ratio at 30 mg/kg, with a significant difference versus control.
Significantly reduced prominent ulcer edges versus control at both 10 mg/kg and 30 mg/kg.
Animal Model: Sprague-Dawley (male, SPF, 220-270g)[2]
Dosage: 1-60 mg/kg (p.o.); 0.3-30 mg/kg (s.c.); 1-30 mg/kg (i.d.); 1-30 mg/kg (i.p.)
Administration: p.o.; single dose (0.5, 3, or 9 hours before pylorus ligation); s.c.; single dose (0.5 hours before pylorus ligation); i.d.; single dose (immediately after pylorus ligation); i.p.; single dose (0.5 hours before pylorus ligation)
Result: Reduced gastric juice volume by 53.1% and acid output by 78.5% at 10 mg/kg p.o.
0.5 hours before ligation, with an ED50 of 4.3 mg/kg for acid output inhibition.
Reduced acid output by 71.7% at 10 mg/kg p.o.
3 hours before ligation, and by 88.0% at 30 mg/kg p.o.
3 hours before ligation, with an ED50 of 5.0 mg/kg.
Reduced acid output by 66.5% at 30 mg/kg p.o.
9 hours before ligation, and by 78.8% at 60 mg/kg p.o.
9 hours before ligation, with an ED50 of 16.9 mg/kg.
Reduced acid output by 71.2% at 1 mg/kg s.c., with an ED50 of 0.7 mg/kg.
Reduced acid output by 65.0% at 3 mg/kg i.d., with an ED50 of 1.1 mg/kg.
Reduced acid output by 64.5% at 10 mg/kg i.p., with an ED50 of 3.6 mg/kg.
Animal Model: Sprague-Dawley (male, SPF, 220-270g)[2]
Dosage: 0.1-30 mg/kg
Administration: s.c.; single dose (0.5 hours before first histamine administration)
Result: Reduced histamine-stimulated acid output by 30.3% at 0.1 mg/kg, 69.3% at 0.3 mg/kg, 73.5% at 1 mg/kg, 89.4% at 3 mg/kg, 92.0% at 10 mg/kg, and 97.5% at 30 mg/kg.
Achieved an ED50 of 0.2 mg/kg for acid output inhibition.
Animal Model: Sprague-Dawley (male, SPF, 220-270g)[2]
Dosage: 0.3-30 mg/kg
Administration: s.c.; single dose (0.5 hours before carbachol infusion)
Result: Reduced carbachol-stimulated acid output by 42.9% at 0.3 mg/kg, 65.5% at 1 mg/kg, 78.1% at 3 mg/kg, 85.6% at 10 mg/kg, and 80.8% at 30 mg/kg.
Achieved an ED50 of 0.3 mg/kg for acid output inhibition.
Animal Model: Sprague-Dawley (male, SPF, 220-270g)[2]
Dosage: 1-30 mg/kg
Administration: s.c.; single dose (0.5 hours before pentagastrin infusion)
Result: Reduced pentagastrin-stimulated acid output by 79.5% at 1 mg/kg, 52.7% at 3 mg/kg, 84.9% at 10 mg/kg, and 98.3% at 30 mg/kg.
Achieved an ED50 of 0.1 mg/kg for acid output inhibition.
Animal Model: Sprague-Dawley (male, SPF, 220-270g)[2]
Dosage: 3-60 mg/kg
Administration: s.c.; single dose (0.5 hours after stimulated secretion stabilized)
Result: Reduced 2-deoxy-D-glucose-stimulated acid output by 65.9% at 60 mg/kg.
Achieved an ED50 of 42.7 mg/kg for acid output inhibition.
Animal Model: Sprague-Dawley (male, SPF, 220-270g)[2]
Dosage: 3-60 mg/kg
Administration: p.o.; single dose (30 minutes before ligation); s.c.; single dose (7 hours after ligation)
Result: Reduced ulcer coefficients by 55.9% at 30 mg/kg, and 61.8% at 60 mg/kg.
Achieved an ED50 of 29.7 mg/kg for ulcer inhibition.
Animal Model: Sprague-Dawley (male, SPF, 220-270g)[2]
Dosage: 1-60 mg/kg
Administration: p.o.; single dose (30 minutes before stress exposure)
Result: Reduced lesion length by 43.1% at 3 mg/kg, 59.1% at 10 mg/kg, 55.8% at 30 mg/kg, and 84.0% at 60 mg/kg.
Achieved an ED50 of 8.4 mg/kg for lesion inhibition.
Animal Model: Sprague-Dawley (male, SPF, 220-270g)[2]
Dosage: 0.3-3 mg/kg
Administration: p.o.; single dose (30 minutes before histamine administration)
Result: Reduced lesion area by 86.7% at 3 mg/kg.
Achieved an ED50 of 0.9 mg/kg for lesion inhibition.
Animal Model: Sprague-Dawley (male, SPF, 220-270g)[2]
Dosage: 3-30 mg/kg
Administration: p.o.; single dose (30 minutes before indomethacin administration)
Result: Reduced lesion length by 52.2% at 10 mg/kg, and 91.8% at 30 mg/kg.
Achieved an ED50 of 5.4 mg/kg for lesion inhibition.
Animal Model: Sprague-Dawley (male, SPF, 220-270g)[2]
Dosage: 1-30 mg/kg
Administration: p.o.; single dose (30 minutes before HCl-aspirin administration)
Result: Reduced lesion length by 78.1% at 3 mg/kg, 90.9% at 10 mg/kg, and 95.0% at 30 mg/kg.
Achieved an ED50 of 1.4 mg/kg for lesion inhibition.
Animal Model: Sprague-Dawley (male, SPF, 220-270g)[2]
Dosage: 3-60 mg/kg
Administration: p.o.; single dose (30 minutes before HCl-ethanol administration)
Result: Reduced lesion length by 62.0% at 20 mg/kg, 77.3% at 30 mg/kg, and 94.1% at 60 mg/kg.
Achieved an ED50 of 17.0 mg/kg for lesion inhibition.
Molecular Weight

455.42

Formula

C22H32Cl2N4O2
CAS No.
SMILES

O=C1N=C(NC/C=C/COC2=CC=CC(CN3CCCCC3)=C2)NC(C)=C1C.Cl.Cl
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

IGN-2098 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

IGN-2098126869-04-3IGN2098IGN 2098Histamine Receptorratsguinea pig atrial specimensacute fistula ratspylorus-ligated ratsgastric mucosal injuryduodenal mucosagastric ulcergastric acid secretioncarbacholhistamine H2 receptorInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
IGN-2098
Cat. No.:
HY-182393
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.